Business
TechCrunch Disrupt SF 2013 - Day 2
Charles River Ventures general partner George Zachary (Steve Jennings/Getty Images)

A venture firm just gave investors their money back instead of investing in a shoddy market

Facing poor market conditions, one venture fund is choosing to downsize.

Earlier this week, I discussed how Lightspeed Venture Partners, a venture capital firm with $25 billion in AUM, appears to be expanding into private equity-like investments with its latest fundraise. Why is Lightspeed diversifying away from traditional venture investing to later stage, PE-like strategies? Because $7 billion in new capital will yield a lot of management fees, but it’s really hard to effectively invest $7 billion in venture capital. Lightspeed’s solution? Allocate a large portion of that capital to mature investments.

Another solution to the market size problem, however, is to raise a smaller fund to more effectively invest in smaller startups, or, in the case of venture firm CRV, return some of the capital that you just raised back to investors. From The New York Times:

The firm (CRV) will tell its investors this week that it will return the $275 million that it has not yet invested from its $500 million Select fund, which is designed to back more mature start-ups.

The reason, four of the firm’s partners said in a joint interview, is that market conditions have changed for the worse. The valuations for start-ups are too high relative to their potential for a payoff, the partners said.

Global venture capital funding reached all-time highs in 2021, with ~$694 billion (an increase of more than 100% from the year prior) being deployed across the venture market that year, but that rapid inflow of capital pushed valuations really, really high as more and more money chased a limited number of deals. Combine climbing valuations with a dismal IPO market, and you have an environment filled with richly-valued companies and investors that can’t offload their stakes.

Given current market conditions, I think we’ll increasingly see venture funds fall into one of these two buckets: AUM conglomerates that diversify into other asset classes to make more management fees, and smaller, tactical venture funds that can still effectively navigate the startup market and find good value. 

Funds that get stuck in the middle around the ~$1 billion range are in a tough spot: it’s difficult to deploy that much capital at reasonable valuations, especially in early-stage companies, and the management fees on a billion-dollar fund still aren’t spectacular, especially if you have a large team.

More Business

See all Business
business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Hims oral semaglutide

Hims, long flying under regulators’ radar, finally strikes a nerve with its Wegovy pill copy

It’s unclear if the pill Hims is selling works or if the FDA will allow it.

$1.3M

There’s still plenty of money to be made in brainrot. The top 1,000 Roblox creators earned an average of $1.3 million in 2025 — up 50% from the year prior — according to CEO Dave Baszucki on the company’s fourth-quarter earnings call.

Roblox paid out $1.5 billion to creators last year, meaning its top 1,000 creators took home about 87% of the total pool.

Like other creator economy giants, Roblox rewards its biggest creators for their contributions to user engagement. Creator-made titles like “Grow a Garden” and “Steal a Brainrot” substantially boosted playing time over the course of the year. In September, the company increased its developer exchange rate, or the ratio of in-game currency to cash payout, by 8.5%.

Texas Governor Abbott And Google Make Economic Development Announcement In Midlothian

Alphabet could buy some pretty huge businesses with the amount of money it plans to spend this year

AI outlays have gone full nut-nut. Even Google, one of the most capital-efficient businesses of all time in its heyday, is spending like there’s no tomorrow.

Tom Jones2/6/26

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.